Kosaraju Nikitha, Moore Lindsay S, Mulders Jip Y, Blevins Nikolas H
Division of Otology/Neurotology, Department of Otolaryngology - Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Rd, Palo Alto, Stanford, CA, 94305-5739, USA.
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Childs Nerv Syst. 2024 Mar;40(3):635-645. doi: 10.1007/s00381-023-06184-9. Epub 2023 Oct 27.
To describe the characteristics, management, and outcomes of pediatric patients with sporadic vestibular schwannoma (sVS).
This was a case series at a tertiary care center. Patients were identified through a research repository and chart review. Interventions were microsurgery, stereotactic radiosurgery (SRS), and observation. Outcome measures were tumor control, facial nerve function, and hearing.
Eight patients over 2006-2022 fulfilled inclusion criteria (unilateral VS without genetic or clinical evidence of neurofibromatosis type 2 (NF2); age ≤ 21) with a mean age of 17 years (14-20). Average greatest tumor length in the internal auditory canal was 9.7 mm (4.0-16.1). Average greatest tumor dimension (4/8 tumors) in the cerebellopontine angle was 19.1 mm (11.3-26.8). Primary treatment was microsurgery in five (62.5%) patients, observation in two (25%), and SRS in one (12.5%). Four (80%) surgical patients had gross total resections, and one (20%) had regrowth post-near total resection and underwent SRS. One observed patient and the primary SRS patient have remained radiographically stable for 3.5 and 7 years, respectively. The other observed patient required surgery for tumor growth after 12 months of observation. Two surgical patients had poor facial nerve outcomes. All post-procedural patients developed anacusis. Mean follow-up was 3 years (0.5-7).
We describe one of the largest reported cohorts of pediatric sVS in the USA. Diligent exclusion of NF2 is critical. Given the high likelihood of eventually requiring intervention and known adverse effects of SRS, microsurgery remains the preferred treatment. However, observation can be considered in select situations.
描述散发型前庭神经鞘瘤(sVS)儿科患者的特征、治疗及预后。
这是一家三级医疗中心的病例系列研究。通过研究资料库和病历审查确定患者。干预措施包括显微手术、立体定向放射外科治疗(SRS)和观察。观察指标为肿瘤控制、面神经功能和听力。
2006年至2022年期间,8例患者符合纳入标准(单侧VS,无2型神经纤维瘤病(NF2)的遗传或临床证据;年龄≤21岁),平均年龄17岁(14 - 20岁)。内耳道内肿瘤平均最大长度为9.7毫米(4.0 - 16.1毫米)。桥小脑角处肿瘤平均最大尺寸(8例中的4例)为19.1毫米(11.3 - 26.8毫米)。5例(62.5%)患者的初始治疗为显微手术,2例(25%)为观察,1例(12.5%)为SRS。4例(80%)接受手术的患者实现了肿瘤全切,1例(20%)在近全切后肿瘤复发,随后接受了SRS。1例接受观察的患者和接受初次SRS治疗的患者分别在3.5年和7年内影像学表现保持稳定。另1例接受观察的患者在观察12个月后因肿瘤生长需要手术。2例接受手术的患者面神经预后较差。所有术后患者均出现全聋。平均随访时间为3年(0.5 - 7年)。
我们描述了美国报道的最大儿科sVS队列之一。严格排除NF2至关重要。鉴于最终需要干预的可能性较高以及SRS已知的不良反应,显微手术仍是首选治疗方法。然而,在特定情况下可考虑观察。